ivr service
      Database Systems Corp. BBB Business Review
   IVR AND VOICE BROADCASTING SERVICES AND SYSTEMS Home  |   Contact Us  |   About Us  |   Sign Up  |   FAQ

ivr software applications


IVRS Software & Services
IVR Customer Satisfaction Surveys
Telemarketing Services
Toll Free Services
Telephone Answering Service
800 Number Services
Voice Messaging Systems
Call Recording Systems
Voice Mail Message
Voice Mail System
Voice Mail Software
Inbound Call Center Services
IVR Hosting
IVR Solutions
IVR Service
IVR Systems
IVR Development Systems
IVR Programming
IVR Design

ivr software applications

Website Information

IVR Software

IVR systems interactive voice response

IVR Solutions

This section of our technical library presents information and documentation relating to Clinical IVR Development and custom IVR software and products. Business phone systems and toll free answering systems (generally 800 numbers and their equivalent) are very popular for service and sales organizations, allowing customers and prospects to call your organization anywhere in the country. The PACER and WIZARD IVR System is just one of many DSC call center phone system features..

What is IVR Software?. An Interactive Voice Response (IVR) processes inbound phone calls, plays recorded messages including information extracted from databases and the internet, and potentially routes calls to either inhouse service agents or transfers the caller to an outside extension.

Contact DSC today. to learn more about our IVR services and IVR application development software.

IVR Depression Severity Assessments Acceptable to FDA in Registration Trials

PharmaLive, www.pharmalive.com

LONDON, November 3, 2004 - The U. S. Food and Drug Administration (FDA) has recently issued a statement regarding the acceptability of Interactive Voice Response (IVR) self-report instruments that assess severity of illness in Major Depressive Disorder and stated that these instruments are acceptable as primary endpoint data in pivotal clinical trials. The assessments mentioned include the Hamilton Depression Rating Scale (HAMD), the Inventory of Depressive Symptomatology (IDS) and the Quick Inventory of Depressive Symptomatology (QIDS).

The notification was issued in a letter to Dr John Greist, CEO of Healthcare Technology Systems (HTS), the world authority in the research, development and validation of computer administered clinical rating instruments. Previously HTS had submitted evidence to the FDA on the effectiveness, validity and advantages of self-report assessments. HTS assessments for all pharmaceutical sponsored Phase I-IV trials are now delivered exclusively by ClinPhone, the global leader in clinical trial management solutions.

Although the FDA’s comments regarding IVR are aimed primarily at research on depression, the statement promises to have far-reaching consequences in the clinical trials industry. Already, the FDA has accepted IVR assessments for migraine, sleep, pain, social phobia and other disorders, and the list is expected to grow. Pharmaceutical sponsors will now be able to choose IVR with the assurance that it has backing from the FDA. This means that both pharmaceutical companies and their patients will be able to reap the benefits that IVR assessments deliver.

Implementing IVR offers several advantages over traditional methods. In the past, patients were assessed by clinical interviewers, but the evidence suggests that there is substantial variability in assessments conducted by clinicians. Further, studies have shown that interviewers may artificially inflate or deflate baseline scores to qualify patients for inclusion in a trial. Using IVR, assessments are standardized and all questions are asked and scored consistently. Additionally, IVR assessments perform error checking during interviews and offer immediate data storage and reduced costs. Finally, patients can call into these automated systems as often as required by the protocol, even doing so from home.

Dr Greist commented, “This communication from FDA extends the use of the IVR HAMD beyond its widely recognized value in controlling rater score inflation at baseline to assessment over time where rater variability may adversely affect trial outcome. Further, accumulated evidence has shown that patient self-reports are accurate and regulators recognize the importance of the patient’s perspective in evaluating drug efficacy.”